CJC-1295 (No DAC) & Ipamorelin research stack — Studied in animal research for their combined role in growth hormone release and body composition. ≥99% purity, Free & Fast delivery.
Original price was: £54.99.£44.99Current price is: £44.99.
-19%CJC-1295 (No DAC) & Ipamorelin is a two-vial research stack pairing a GHRH analogue with a selective growth hormone secretagogue — the two most-studied peptides in the growth-hormone research space, supplied as two separate 5mg vials rather than a pre-mixed blend.
In animal research, CJC-1295 (No DAC) and Ipamorelin have been studied for their combined role in:
The reason researchers pair them is that they act on two different receptors: CJC-1295 (No DAC) on the GHRH receptor, Ipamorelin on the ghrelin/GHS receptor — one providing an immediate GH pulse, the other sustaining the signal.
Prefer the compounds individually? See the CJC-1295 (No DAC) solo and Ipamorelin solo pages. Reconstitute with our bacteriostatic water and syringes.
For research use only. This product is intended strictly for laboratory research purposes and is not for human or animal consumption, medical use, or diagnostic use. Not a drug, food, or cosmetic.
It pairs CJC-1295 in its short-acting No-DAC form — a growth-hormone-releasing hormone (GHRH) analogue — with Ipamorelin, a selective growth hormone secretagogue. Supplied as two separate 5mg vials, it is the most-searched growth hormone peptide combination. For the detail on the No-DAC versus DAC forms, see the CJC-1295 (No DAC) page.
Both peptides raise the body’s own growth hormone, and in the research literature higher growth hormone is linked to lean muscle, body fat, recovery and sleep. In animal and clinical research the individual compounds have been studied for:
Direct studies on the combination in people are limited; the rationale rests on each compound’s research and the established growth hormone pathway.
Yes — in animal research Ipamorelin has been studied for its effect on body fat and adiposity (Lall 2001), and raised growth hormone is associated in the literature with fat metabolism. It is one of the most common reasons the stack is researched, though direct fat-loss studies on the combination in humans are limited.
Both compounds raise growth hormone and IGF-1 (Teichman 2006; Jetté 2005), which the research literature links to lean muscle and body composition. The pairing is studied for this combined effect on the growth hormone axis rather than for any direct anabolic action.
Growth hormone is released mainly during deep sleep and is associated in research with tissue repair and recovery. By raising the body’s own growth hormone output, CJC-1295 and Ipamorelin are studied in this context.
They act on two different receptors, which is why they are paired. CJC-1295 (No DAC) acts on the GHRH receptor to raise the amount of GH in each natural pulse; Ipamorelin acts on the ghrelin/GHS receptor to trigger a pulse. In research the combination is studied to see whether acting on both pathways produces a larger, cleaner release than either alone — one giving an immediate pulse, the other sustaining the signal.
| Compound | Research area studied (animal / preclinical) | Reference |
|---|---|---|
| CJC-1295 (No DAC) | GRF-receptor activation & pulsatile GH release | Jetté 2005 |
| CJC-1295 | GH / IGF-1 pharmacology | Teichman 2006 |
| Ipamorelin | Selective GH release (no cortisol/prolactin rise) | Raun 1998 |
| Ipamorelin | Body fat / adiposity in animal models | Lall 2001 |
| Ipamorelin | Bone mineral density in animal models | Svensson 2000 |
Further reading: Should you mix CJC-1295 and Ipamorelin, or keep them as separate vials?
All references verified against PubMed (10 July 2026).
For research use only. Not for human or animal consumption. The references above describe laboratory and animal research and are provided for scientific context only; they are not claims about effects in humans.
